Market News

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cronos Group Inc. resulting from allegations that Cronos may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cronos securities you may be entitled to compensation without payment of any out of pocket fees or costs ...

-

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cronos Group Inc. (NASDAQ: CRON) resulting from allegations that Cronos may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Cronos securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to http://www.rosenlegal.com/cases-register-2202.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On November 9, 2021 , Cronos filed a Form 8-K with the SEC in which it disclosed that it had determined the previous day that the Company would "be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021 " and that "[t]he Company's financial statements for this period should therefore no longer be relied upon." On this news, Cronos' share price dropped nearly 16%, damaging investors.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ .

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/cron-investor-notice-rosen-a-leading-national-firm-encourages-cronos-group-inc-investors-with-losses-to-inquire-about-class-action-investigation--cron-301437325.html

SOURCE Rosen Law Firm, P.A.

News Provided by PR Newswire via QuoteMedia

business meeting evaluating financial results

Cannabis Weekly Round-Up: Organigram Results Improve, Ascend Ready for Lawsuit

A Canadian cannabis producer beat estimates in its latest financial results, and experts believe it may be showing signs of achieving profitability.

Also this week, Ascend Wellness Holdings (AWH) (CSE:AAWH.U,OTCQX:AAWH) revealed it will be taking its dispute with MedMen Enterprises (CSE:MMEN,OTCQX:MMNFF) to court.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading... Show less
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

The trial evaluates Numinus' first trademarked product and patent-pending production process

 Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application ("CTA") to Health Canada for its Phase 1 study, HOPE, on a naturally derived Psilocybe extract formulation, NBIO-01. This milestone further progresses and solidifies Numinus' long-standing work on developing safe and effective psychedelic products out of its Health Canada-licensed research facility, Numinus Bioscience.

Keep reading... Show less
Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

Expansion and fortification of relationship since 2020 with established pharmaceutical company in Chile

Supply of Avicanna's active pharmaceutical ingredients for existing commercial and pipeline of pharmaceutical products in South America

Keep reading... Show less
Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that its annual general meeting of shareholders (the "AGM"), which was originally scheduled to be held on Friday, January 21, 2022 has been cancelled and rescheduled to be held on February 28 2022. The Company's Board of Directors determined that it would be in the best interests of the Company to reschedule the AGM for a variety of reasons, including a change to at least one resolution.

Further details on the AGM will be contained in a new Notice of Meeting and Management Information Circular that will be mailed to shareholders of the Company and filed on SEDAR.

Keep reading... Show less

IIROC Trade Resumption - CL

Trading resumes in:

Company: Cresco Labs Inc.

Keep reading... Show less

IIROC Trading Halt - CL

The following issues have been halted by IIROC:

Company: Cresco Labs Inc.

Keep reading... Show less

Latest Press Releases

Related News

×